Feature | August 01, 2014

Fundamental Research Is Paving the Way for Development of First Vaccine for Heart Diseases

Clinical Study Heart Vaccine Pharmaceutical

August 1, 2014 — Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step closer to the goal of developing the world’s first T-cell peptide-based vaccine for heart disease — the number one killer in the nation.

Atherosclerosis is a chronic inflammatory disease of the arterial walls, which thicken due to accumulation of fatty materials such as cholesterols and triglycerides. Blocking of arteries supplying blood to the heart is the underlying cause of many heart diseases. Nearly 600,000 Americans die of heart disease every year. Although cholesterol is believed to be a major factor in creating the plaque that leads to heart disease, immune inflammation is another important contributor in arterial plaque buildup. The goal of the vaccine is to reduce immune-based inflammation in the arteries, leading to decreased plaque buildup.

The scientists published their findings in the December 2013 issue of Frontiers in Immunology, entitled "Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100." These experiments show proof of concept for the development of an autoantigen-specific vaccine for reducing the amount of atherosclerotic plaques in mice. If successful, the vaccine could aid in preventing heart disease and stop or reduce disease progression. In addition to heart disease, the vaccine could target strokes, which are also a product of plaque buildup in arteries.

The published work, performed in the laboratory of Klaus Ley, M.D., a prominent vascular biologist of LIAI, was based on the fundamental discovery made by Harley Tse, Ph.D., professor of immunology and microbiology in Wayne State’s School of Medicine, and professor in Wayne State’s Cardiovascular Research Institute, and Michael Shaw, Ph.D., adjunct assistant professor of immunology and microbiology at Wayne State. Shaw and Tse are the first to demonstrate that two T cell epitopes of the autoantigen apoB100 are deeply involved in the development of the disease. Their novel discovery is reported in the article, “Identification of two Immunogenic T cell Epitopes of ApoB-100 and their Autoimmune Implications,” published in the April – June 2014 issue (volume 2) of Journal of Immunology and Clinical Research.

“ApoB100 is an apolipoprotein of the LDL (low-density lipoprotein) particle, which is the notorious ‘bad cholesterol’ that contributes to the formation of plaques in the vessel wall,” said Tse. “Although T cells of the immune system are known to participate in the development of heart disease, by what and how these T cells are directed to act have not been elucidated. The lack of this knowledge has greatly hampered the development of immune peptide-based therapeutics to control the disease. With the discovery of the disease-causing T cell epitopes, we can now manipulate the activities of the T cells responding to these epitopes to control the disease.”

Since immune T cells are normally activated by a short sequence (called an epitope), and not by the whole molecule of an antigen, Shaw and Tse conceptualized that finding the apoB100 epitopes capable of stimulating the disease causing (atherogenic) T cells is a prerequisite for understanding how these T cells are involved in heart disease development and for finding ways to control their adverse effects.

Based on this idea, they identified two short sequences (3501–3515 and 978–992) of ApoB100 (ApoB3501-3515 and ApoB978-992, also designated peptides P3 and P6, respectively) that were able to direct specific T cells to proliferate as well as to cause worsening atherosclerosis. This discovery is significant because it identifies the target T cells and makes it possible to manipulate this population of pathologic T cells away from their harmful activities.

The subsequent collaboration with Ley’s laboratory bears the first fruits of this effort.

Substantial funding for Tse’s research was provided by the Office of the Vice President for Research at Wayne State University.

For more information: www.research.wayne.edu

Related Content

News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in
NICE, U.K., edoxaban, Lixiana, VTE, venous thromboembolism, deep vein thrombosis, pulmonary embolism
News | Deep Vein Thrombosis| August 12, 2015
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering...
Boehringer Ingelheim, RE-DUAL PCI, RE-CIRCUIT, Pradaxa, first U.S. patients,
News | Antiplatelet and Anticoagulation Therapies| August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S.
triple therapy, dual antiplatelet therapy, atrial fibrillation, heart attack, older patients, JACC
News | Antiplatelet and Anticoagulation Therapies| August 04, 2015
Triple therapy is no better than dual antiplatelet therapy in preventing major adverse cardiac events in older patients...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab| July 22, 2015
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Cartoon representation of a deformable platelet-like particle with fibrin nanobodies attached

Feature | Antiplatelet and Anticoagulation Therapies| July 13, 2015
Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies| July 07, 2015
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab...
ACC, Statin Intolerance App, statin therapy, muscle symptoms, pain
Technology | July 01, 2015
The American College of Cardiology (ACC) Statin Intolerance App is now available to help guide clinicians through the...
cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
Technology | June 22, 2015
The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as...
Overlay Init